Category: Analyst’s Comments

Sonnet Biotherapeutics Holdings Inc (SONN) stock rallied in the Pre-Market today on October 4, 2021. SONN stock price saw a push of 7.69% to reach $0.70 a share at the time of this writing. The stock was also green in the previous trade and went up by 7.1% bringing per share price $0.649 at closing. Let’s understand the reason behind this bull. What’s Happening? There is no recent or press release by Sonnet Biotherapeutics today not even in the previous week to justify the bullish sentiment. No analyst has upgraded or increased the targeted per share price of the SONN

Farmmi, Inc. (FAMI) has surged 12.44% in the premarket today after the company issues a CEO update letter. However, the last trading session closed at $0.3536 with a decrease of 23.55%. CEO Update Letter FAMI issued a CEO update letter on 3rd October 2021. The company sent a CEO update letter outlining an acquisition that enlarged the Company’s addressable market, as well as the company’s plans for enhanced growth and expanded possibilities. According to the letter, FAMI has come a long way in the last 20 years, as they have established itself as an industry leader in the production, processing,

Adverum Biotechnologies, Inc. (ADVM) experiences an incline of 18.35% in the aftermarket. However, the last trading session closed at $2.18 with an increase of 0.46%. 2-Year OPTIC Data Demonstrating Sustained Durability On 1st October 2021, ADVM announced new long-term results from the OPTIC clinical trial of ADVM-022. It is a single, in-office intravitreal (IVT) injection gene therapy in patients with neovascular or wet age-related macular degeneration. The Retina Society’s 54th Annual Scientific Meeting in Chicago, Illinois, will provide safety and effectiveness data from patients who were tracked for two years after injection. The presentation may be seen on Adverum’s website’s

Quantum Computing, Inc. (QUBT) saw a decline of 6.96% in the aftermarket. However, the last trading session closed at $6.18 with a downfall of 0.72%. New Appointment to Board of Directors On 23rd September 2021, QUBT appointed William J. McGann to the company’s board of directors. McGann has more than 30 years of senior leadership, technology, and scientific expertise. Not only this, but he has a strong desire to transform new technologies into practical answers. He has been the Chief Technology Officer for Leidos Corp.’s Security, Detection, and Automation unit since 2019. Also, he is responsible for developing novel client

INmune Bio, Inc. (INMB) saw a decline of 6.77% in the aftermarket. However, the last trading session closed at $20.38 with an increase of 4.94%. Reduction in CSF Phospho-Tau and Evidence of Remyelination On 1st September 2021, INMB announced that Alzheimer’s Patients Treated with INmune Bio’s XPro Show Reduction in CSF Phospho-Tau and Evidence of Remyelination. XProTM (pegipanermin) is the Company’s selective DN-TNF inhibitor candidate for the treatment of Alzheimer’s disease (AD). It has been found to lower numerous species of Phospho Tau (pTau) and improve neuroimaging biological markers of myelination in patients with AD. These biomarker results come from

Shares of EyeGate Pharmaceuticals, Inc. (EYEG) stock were declining in the intraday session today on October 1, 2021. EYEG stock price saw a downtrend of 7.21% to drop at $2.09 a share at the time of this writing. The stock was green in the previous trade following Zack’s report that discussed the pipeline expansion of stock from one to three candidates. Let’s deep dive to explore more of it. What’s Happening? There is no major culprit behind the falling stock price of the EYEG stock today. No analyst degrades or decreased targeted per share price of the EyeGate have been

Comstock Mining Inc. (LODE) saw a fall of 5.24% in the premarket on 1st October 2021. However, the last trading session concluded at $2.67 with an incline of 3.09%. LODE Commences Production at Mercury and Gold Extraction Facility LODE announced on 22 September 2021 that Clean Mercury Remediation Technologies has acquired the final permission and begun full operations in the company’s first commercial mercury remediation system in the Philippines. To dissolve gold from natural sources, mercury-dependent ASGM employs the amalgamation process. Usually, the amalgam is separated by hand and then heated to remove the mercury and isolate the gold. Mercury

Aeterna Zentaris Inc. (AEZS) has experienced an increase of 11.87% in the aftermarket. However, the last trading session closed at $0.75 with an incline of 25.63%. Second Quarter 2021 Financial Results AEZS reported second-quarter 2021 financial results on 4th August 2021. Firstly, the total revenue for the three months was $0.60 million. Secondly, licensing revenue of $0.5 million, supply chain revenue of $0.04 million, and royalty income of $0.02 million comprised the revenue for 2021. The licensing income was obtained by recognizing a portion of the delayed €5 million payment from Novo Nordisk that was received in the fourth quarter

Bridgeline Digital, Inc. (BLIN) stock popping high today after it announced a new launch update in its Salesforce AppExchange. BLIN stock price saw a push of 4.04% to reach $4.00 a share at the time of this writing. Let’s take a closer look at this stock and its recent events. Bridgeline Digital, Inc is a digital engagement company that provides a platform to companies to develops their websites, web applications, and online stores. The company also offers content management systems, to create, edit and publish content through a browser-based interface. The company is also involved in providing eCommerce solutions to

TDH Holdings Inc. (PETZ) stock prices were down by 1.08% as of the market closing on September 29th, 2021. This brought the price per share down to USD$1.84 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 16.85%, bringing it up to USD$1.53. Securities Purchase Agreement September 30th, 2021 saw PETZ stock announce having entered into a securities purchase agreement with certain investors. The agreement will facilitate a registered direct placement of USD$9.1 million in common shares and accompanying warrants. Each share has been priced at USD$0.89, with each warrant being valued at